Zoetis
ZTS
71.55
+0.22
+0.31%
Zoetis
US · ZTS
#700 by market cap
Listed 1970
71.55
+0.22
+0.31%
Live - 5344 symbols - heartbeat 495s ago
· 2026-10-08 07:40
Pre-market
71.55
0.00%
After-hours
71.55
0.00%
Overnight
71.73
+0.25%
- Market cap
- 29.57B
- P/E (TTM)i
- 11.67
- P/Bi
- 9.39
- EPSi
- 6.02
- Div yieldi
- 2.88%
- 52W posi
- 4%
Reader sentiment
Are you bullish or bearish on ZTS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 11 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.3 percentage points.
Institutional ownership
- Held by institutions
- 98.67% -0.33pp
- Institutions
- 1,819 -11
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund75.53%
Private Company7.51%
Public Company5.31%
Hedge Fund5.11%
Government Pension Fund2.21%
Sovereign Wealth Fund1.16%
Family Office/Trust0.55%
VC/PE Fund0.47%
Insurance Company0.31%
Other1.84%
Top holders as of 2026-06-30
BlackRock
9.54% · 39.43M sh
Vanguard Capital Management, LLC
6.87% · 28.39M sh
Vanguard Portfolio Management, LLC
5.77% · 23.86M sh
State Street Global Advisors
4.76% · 19.67M sh
State Farm Mutual Automobile Insurance Company
3.85% · 15.89M sh
Geode Capital Management, LLC
3.22% · 13.29M sh
Wellington Management Group
2.28% · 9.42M sh
UBS Asset Management
1.83% · 7.57M sh
Nordea Investment Management AB
1.60% · 6.59M sh
Deutsche Asset & Wealth Management
1.39% · 5.74M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 39 buys · 7 sells
| Name | Role | Stake |
|---|---|---|
| Kristin Peck | Chief Executive Officer | 0.03% |
| Michael McCAllister | Independent Non-Executive Chairperson | 0.01% |
| Heidi Chen | Executive VP, General Counsel, Corporate Secretary & Business Lead of Human Health Diagnostics | 0.01% |
| Robert Scully | Independent Director | 0.01% |
| Louise Parent | Independent Director | 0.01% |
| Paul Bisaro | Independent Director | 0.01% |
| Wetteny Joseph | Chief Financial Officer | 0.01% |
| Frank D'Amelio | Independent Director | 0.01% |
| Gregory Norden | Independent Director | 0.00% |
| Roxanne Lagano | Executive VP and Chief Human Resources Officer & Global Operations | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Julie Fuller | Executive VP, Chief Human Resources Officer & Global Operations | Derivative Exercise and Sale | -274 | $69.83 |
| 2026-09-29 | Julie Fuller | Executive VP, Chief Human Resources Officer & Global Operations | Derivative Exercise and Retained | +525 | -- |
| 2026-09-16 | Mark Stetter | Independent Director | Other Derivative Acquisition | +342 | -- |
| 2026-08-30 | James Saccaro | Chief Financial Officer | Other Derivative Acquisition | +81,063 | -- |
| 2026-08-06 | Frank D'Amelio | Independent Director | Other Disposition | -6,650 | -- |
| 2026-07-09 | Wetteny Joseph | Chief Financial Officer | Other Derivative Acquisition | +363 | -- |
| 2026-07-09 | Kristin Peck | Chief Executive Officer | Other Derivative Acquisition | +616 | -- |
| 2026-07-09 | Roxanne Lagano | Executive VP and Chief Human Resources Officer & Global Operations | Other Derivative Acquisition | +314 | -- |
| 2026-07-09 | Abhay Nayak | Former Executive VP and Head of Strategy, Accelerated Growth Businesses & Commercial Development | Other Derivative Acquisition | +214 | -- |
| 2026-07-09 | Julie Fuller | Executive VP, Chief Human Resources Officer & Global Operations | Other Derivative Acquisition | +314 | -- |
| 2026-07-09 | Jeannette Astorga | Executive VP of Corporate Affairs & Communications and Chief Sustainability Officer | Other Derivative Acquisition | +45 | -- |
| 2026-07-09 | Rimma Driscoll | Head of Global Strategy, Commercial & Business Development and Global BioDevices | Other Derivative Acquisition | +237 | -- |
| 2026-07-09 | Keith Sarbaugh | Executive VP & Chief Digital and Technology Officer | Other Derivative Acquisition | +259 | -- |
| 2026-07-09 | Kevin Esch | Senior Vice President of Global Therapeutics | Other Derivative Acquisition | +308 | -- |
| 2026-06-17 | Mark Stetter | Independent Director | Other Derivative Acquisition | +317 | -- |
| 2026-06-14 | Abhay Nayak | Former Executive VP and Head of Strategy, Accelerated Growth Businesses & Commercial Development | Initial Statement of Beneficial | 0 | -- |
| 2026-06-09 | Michael McCAllister | Independent Non-Executive Chairperson | Other Disposition | -1,209 | -- |
| 2026-05-20 | Mark Stetter | Independent Director | Derivative Exercise and Retained | +1,572 | -- |
| 2026-05-19 | Louise Parent | Independent Director | Derivative Exercise and Retained | +12,130 | -- |
| 2026-05-12 | Paul Bisaro | Independent Director | Open Market Acquisition | +2,000 | $75.88 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:40:18 · For reference only, not investment advice and not tailored to your situation.